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cardiovascular (CV) risk of NSAIDs, partially triggered by the withdrawal of rofe-
coxib. Small increases in BP associated with NSAID use contribute to the CV toxicity 
of NSAIDs. OA patients often have an elevated risk for CV events due to characteris-
tics common to this population; advanced age, obesity, and co-morbidities such as 
diabetes, hypertension and other CV risks. In order to quantify the potential health 
economic beneﬁts of improvement in the BP proﬁle of NSAIDs, an individual state 
transition model (one year cycles, 5-year treatment duration, life-time model horizon, 
health care perspective) encompassing eight CV events (congestive heart failure, stroke, 
transient ischemic attack, myocardial infarction, stable angina, unstable angina, stroke 
death and MI death) caused or exacerbated by increases in BP was constructed. The 
model was populated with UK data. The model was used to estimate potential cost 
savings and QALY beneﬁts from avoided cardiovascular events associated with four 
levels of relative risk reductions (RRRs) with a hypothetical NSAID (5%, 10%, 15%. 
20% and 25%) compared to naproxen—widely regarded the NSAID with the most 
benign CV proﬁle currently on the market—at three levels of absolute 10-year primary 
CV risk (20%, 30% and 40%). RESULTS: As expected the cost savings and QALY 
beneﬁts associated with avoided cardiovascular events increased with the level of RRR 
and 10-year absolute CV risk. Potential cost savings ranged from GBP 181 to GBP 
1,591, whereas the QALY beneﬁts ranged from 0.05 to 0.44. CONCLUSIONS: An 
NSAID with an improved BP proﬁle has the potential to provide signiﬁcant health 
economic beneﬁts, especially in patients with elevated CV risk.
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OBJECTIVES: Analyse the costs and outcome of treating osteoporosis in Germany 
with either a combination of Alfacalcidol, Alendronate and 500 mg calcium (regime 
1) or plain vitamin D, Alendronate and 1000 mg calcium (regime 2). METHODS: A 
Markov model was created and a time horizon of 2, 5 and 10 years were evaluated. 
Patients could be in the state of well, fracture, post fracture and dead. Data were 
extracted from published clinical trials and register based studies. RESULTS: Treat-
ment regime 1 are associated with lower costs compared to treatment regime 2. The 
drug costs in regime 1 are above the drug costs in regime 2 (a2191/patient vs. a1392/
patient). However, when taking into account that the risk of fractures is signiﬁcantly 
lower for patients treated in regime 1, treatment regime 1 becomes cost saving over 
a 2 year time horizon compared to regime 2 (a3142/patient vs. a4782/patient). Regime 
1 is also the most effective alternative measured in QALYs. On a 2 year time horizon 
the patients in treatment regime 1 gain 1.4956 QALYs. In comparison, patients from 
regime 2 gains 1.4242 QALYs, i.e. regime 1 is dominating regime 2. In 2003, around 
7.8 million Germans, or around 25% of the population above the age of 50, were 
estimated to suffer from osteoporosis. Taking into account the savings per patient 
when treating with regime 1, there is a signiﬁcant saving potential for Germany. 
CONCLUSIONS: Lowest total cost of treatment is obtained when osteoporosis 
patients are treated with Alfacalcidol in combination with Alendronate and 500 mg 
calcium. Even though the initial cost of plain vitamin D, Alendronate 1000 mg 
calcium is lower, the Alfacalcidol regime is more cost effective, due to a signiﬁcantly 
lower risk of fractures. Furthermore, the Alfacalcidol regime is more effective mea-
sured in QALYs.
PMS49
COST-UTILITY ANALYSIS OF LEFLUNOMIDE (ARAVA) IN THE 
TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND
Plisko R1, Krzystek J1, Lis J2, Rys P1
1HTA Consulting, Krakow, Poland, 2Sanoﬁ-Aventis, Warsaw, Poland
OBJECTIVES: To evaluate the cost-effectiveness of leﬂunomide used before tumor 
necrosis factor (TNF) inhibitors compared with leﬂunomide after TNF inhibitors in 
the sequence treatment of rheumatoid arthritis (RA) following the failure of 2 disease-
modifying antirheumatic drugs (DMARDs) in Polish setting. METHODS: A cost-
utility approach was adopted, evaluating total direct costs incurred by the National 
Health Fund (NHF) and quality-adjusted life years (QALY). A micro-simulation 
Markov model was used to estimate utilities and costs. Simulation was executed in 6 
months cycles and terminated at the time of the patient’s death. Transition probabili-
ties between health states were calculated based on a systematic review of RCTs and 
supplemented with published literature if necessary. Health states utilities were taken 
from published literature. Probabilistic sensitivity analysis was performed. The starting 
time-point of the model was the failure of two previous DMARDs. Six treatment 
options were compared. Upon treatment failure it was assumed patients would follow 
an identical lifetime treatment strategy consisting of: LIM—leﬂunomide, inﬂiximab, 
methotrexat, LEM—leﬂunomide, etanercept, methotrexat, LAM—leﬂunomide, adali-
mumab, methotrexat, ILM—inﬂiximab, leﬂunomide, methotrexat, ELM—etanercept, 
leﬂunomide, methotrexat, ALM—adalimumab, leﬂunomide, methotrexat. RESULTS: 
Sequences with leﬂunomide at the beginning of the RA treatment (LIM, LAM, LEM) 
were dominant over schedules with leﬂunomide used after TNF inhibitors (ILM, ELM, 
ALM). Detailed results: LIM vs. ILM (cost difference—7,788 PLN, QALY difference 
—0.002); LEM vs. ELM (cost difference—18,871 PLN, QALY difference—0.004); 
LAM vs. ALM (cost difference—11,377 PLN, QALY difference—0.016). CONCLU-
SIONS: The model predicted that leﬂunomide should be used before TNF inhibitors. 
LEM, LAM, LIM sequences for RA patients who have failed DMARDs therapy are 
less costly and more effective than sequences with leﬂunomid administrated after TNF 
inhibitors (ILM, ELM, ALM).
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INTRODUCTION: Osteoporosis is a common illness frequently leading to serious 
adverse outcomes for patients. Hip, wrist and vertebral fractures have considerable 
impact on both costs to health care system and lives of those who suffer from those 
events. Each year in the US, an estimated 1.5 million fractures occur due to osteopo-
rosis [Riggs and Melton, 1995]. Estimated incremental cost of osteoporosis related 
events in subsequent years after fracture is US$4.007 [Rousculp, 2007]. Bisphospho-
nates are widely used and are considered an effective intervention for risk reduction 
of postmenopausal fractures. OBJECTIVES: The present study was conducted to 
compare the cost of bisphosphonates used for risk reduction of post-menopause ver-
tebral and non-vertebral fractures under public payer (SUS) perspective in Brazil. 
METHODS: The most important bisphosphonates in the public market are ibandro-
nate (oral and IV), zolendronate, alendronate and risendronate. There are no head-
to-head clinical trials comparing all compounds. Studies of ibandronate IV [Eisman, 
2008] and zolendronate IV [McClung, 2007] demonstrated their non-inferiority 
against oral bisphosphonates. Therefore, a cost-minimization approach was taken. 
Drug acquisition costs took into account was the maximum sales price to government. 
Administration costs were obtained from SUS reimbursement database (SIA/SUS, 
2006). Since the time horizon of this analysis is one-year, no discount rate was utilized. 
Costs are presented in Brazilian Reais (US$1.00^R$2.00 in May 2009). RESULTS: 
Total cost per patient was R$814.12 for IV ibandronate, R$915.59 for alendronate, 
R$1054.32 for oral ibandronate, R$1054.97 for zolendronate and R$1278.81 for 
risendronate. Administration costs represented about 9% and 2% of total cost of 
ibandronate (administrated four times a year) and zolendronate (administrated once 
a year), respectively. CONCLUSIONS: Findings suggest IV ibandronate is a cost-
saving therapy with potential of reducing total treatment cost per patient from 11% 
to 36%, when compared to alendronate and risedronate respectively, under public 
payer perspective.
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BACKGROUND: Osteoporosis is a common illness frequently leading to serious 
adverse outcomes for patients. Hip, wrist and vertebral fractures have considerable 
impact on both costs to health care system and lives of those who suffer from those 
events. Each year in the US, an estimated 1.5 million fractures occur due to osteopo-
rosis [Riggs and Melton, 1995]. Estimated incremental cost of osteoporosis related 
events in subsequent years after fracture is US$4007 [Rousculp, 2007]. Bisphospho-
nates are widely used and are considered an effective intervention for risk reduction 
of postmenopausal fractures. OBJECTIVES: The present study was conducted to 
compare the cost of IV bisphosphonates used for risk reduction of post-menopause 
vertebral and non-vertebral fractures under the private payer perspective in Brazil. 
METHODS: According to local legislation, private payers are not obliged to cover 
oral drugs, therefore, oral forms of biphosphonates were not considered in this study. 
The most important IV bisphosphonates in the private market are ibandronate and 
zolendronate. There are no head-to-head clinical trials comparing both compounds. 
Both studies of ibandronate [Eisman, 2008] and zolendronate [McClung, 2007] dem-
onstrated their non-inferiority against oral bisphosphonates. Therefore, a cost-
 minimization approach was taken. Drug prices were obtained from ofﬁcial public 
sources (Kairos Magazine, May 2009). Administration costs were obtained from 
medical society physicians fee list (CBHPM, 2008, v.5). Since the time horizon of this 
analysis is one-year no discount rate was utilized. Costs are presented in Brazilian 
Reais (US$1.00^R$2.00 in May 2009). RESULTS: Total cost per patient was 
R$1534.36 for ibandronate and R$1951.26 for zolendronate. Administration costs 
represented about 11% of total cost of ibandronate (administrated four times a year) 
and 2% for zolendronate (administrated once a year). CONCLUSIONS: Findings 
suggest that IV ibandronate is a cost-saving therapy with potential to yield 21% 
reduction in total cost per patient under Brazilian private payer.
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BACKGROUND: Osteoporosis is a common illness frequently leading to serious 
adverse outcomes for patients. Hip, wrist and vertebral fractures have a considerable 
impact on both costs to health care system and lives of those who suffer from those 
events. Each year in the US, an estimated 1.5 million fractures occur due to osteopo-
rosis [Riggs and Melton, 1995]. Estimated incremental cost of osteoporosis related 
events in the subsequent years after fracture is US$4007 [Rousculp, 2007]. Bisphos-
